Accuray withdraws outlook as Q3 revenue falls, loss widens

Accuray

06/05/2026 21:35

Overview

Radiation therapy systems maker's fiscal Q3 revenue fell 7% and missed analyst expectations

Company posted wider net loss and diluted EPS loss vs prior year period

Accuray withdrew fiscal 2026 guidance due to Middle East geopolitical uncertainty impacting shipments

Outlook

Company withdraws fiscal 2026 financial guidance due to geopolitical uncertainty in the Middle East

Accuray plans to revisit its outlook when it reports fiscal fourth quarter results

Result Drivers

TRANSFORMATION PLAN - Co said approximately $10 mln in cost and margin improvements were realized through transformation initiatives

HIGHER COSTS - Gross margin decline was primarily due to higher net parts consumption and increased logistics and duties costs

GEOPOLITICAL DELAYS - Co said geopolitical uncertainty in the Middle East led to delayed product shipments and service revenue, prompting withdrawal of guidance

Company press release: ID:nPn5bQ8Vha

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$104.85 mln
$111.90 mln (2 Analysts)
Q3 Net Income
-$11.81 mln
Q3 Basic EPS
-$0.09
Q3 Gross Profit
$25.29 mln
Q3 Income From Operations
-$9.09 mln
Q3 Operating Expenses
$34.38 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Accuray Inc is $2.53, about 448% above its May 5 closing price of $0.46

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)